No products in the cart.
Pre-made Polatuzumab benchmark antibody ( Whole mAb ADC, anti-CD79B therapeutic antibody, Anti-AGM6/B29/IGB Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-449
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Polatuzumab biosimilar, Whole mAb ADC, Anti-CD79B Antibody: Anti-AGM6/B29/IGB therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Polatuzumab vedotin contains a monoclonal antibody that binds to a protein called CD79B, which is found on B cells (a type of white blood cell) and some lymphoma cells. It also contains an anticancer drug, which may help kill cancer cells. Polatuzumab vedotin is a type of antibody-drug conjugate. Also called Polivy.
| Products Name (INN Index) | Pre-Made Polatuzumab biosimilar, Whole mAb ADC, Anti-CD79B Antibody: Anti-AGM6/B29/IGB therapeutic antibody |
|---|---|
| INN Name | Polatuzumab |
| Target | CD79B |
| Format | Whole mAb ADC |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2012 |
| Year Recommended | 2013 |
| Companies | Chugai Pharmaceutical,Genentech,Roche |
| Conditions Approved | Diffuse large B cell lymphoma |
| Conditions Active | Non-Hodgkin's lymphoma,Follicular lymphoma |
| Conditions Discontinued | Chronic lymphocytic leukaemia |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CD79B |
| Package |
Previous slide
Next slide
